Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:21 pm Sale |
2023-12-31 | 13G | Ascendis Pharma A/S ASND |
Baker Bros. Advisors LP | 0 0.000% |
-4,954,855 (Position Closed) |
Filing History |
| 2024-02-14 4:21 pm Purchase |
2023-12-31 | 13G | Athira Pharma, Inc. ATHA |
Baker Bros. Advisors LP | 3,153,807 8.300% |
3,153,807 (New Position) |
Filing History |
| 2024-02-14 4:21 pm Sale |
2023-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
Baker Bros. Advisors LP | 10,204,089 4.980% |
-8,980,705 (-46.81%) |
Filing History |
| 2024-02-14 4:21 pm Purchase |
2023-12-31 | 13G | Biomea Fusion, Inc. BMEA |
Baker Bros. Advisors LP | 2,108,949 5.900% |
4,390 (+0.21%) |
Filing History |
| 2024-02-14 4:21 pm Purchase |
2023-12-31 | 13G | Kala Pharmaceuticals, Inc. KALA |
Baker Bros. Advisors LP | 269,213 9.990% |
88,300 (+48.81%) |
Filing History |
| 2024-02-12 4:10 pm Purchase |
2024-01-31 | 13G | Bicycle Therapeutics plc BCYC |
Baker Bros. Advisors LP | 4,823,598 12.800% |
4,823,598 (New Position) |
Filing History |
| 2024-02-01 5:25 pm Sale |
2024-01-30 | 13D | Immunocore Holdings plc IMCR |
Baker Bros. Advisors LP | 2,452,871 4.990% |
-2,232,819 (-47.65%) |
Filing History |
| 2024-01-10 4:58 pm Purchase |
2023-12-31 | 13G | Sera Prognostics, Inc. SERA |
Baker Bros. Advisors LP | 5,434,399 17.900% |
5,434,399 (New Position) |
Filing History |
| 2024-01-10 4:57 pm Purchase |
2023-12-31 | 13G | Replimune Group, Inc. REPL |
Baker Bros. Advisors LP | 9,545,336 16.200% |
3,777,109 (+65.48%) |
Filing History |
| 2024-01-10 4:52 pm Purchase |
2023-12-31 | 13G | Atreca, Inc. BCEL |
Baker Bros. Advisors LP | 7,677,982 19.990% |
4,145,222 (+117.34%) |
Filing History |
| 2024-01-10 4:52 pm Purchase |
2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Baker Bros. Advisors LP | 5,995,928 10.800% |
3,116,103 (+108.20%) |
Filing History |
| 2023-12-20 5:24 pm Purchase |
2023-12-18 | 13D | Neurogene Inc. NGNE |
Baker Bros. Advisors LP | 649,685 4.990% |
649,685 (New Position) |
Filing History |
| 2023-12-18 5:25 pm Sale |
2023-12-14 | 13D | Seagen Inc. SGEN |
Baker Bros. Advisors LP | 0 0.000% |
-45,074,469 (Position Closed) |
Filing History |
| 2023-12-15 5:20 pm Purchase |
2023-12-15 | 13D | IGM Biosciences, Inc. IGMS |
Baker Bros. Advisors LP | 3,744,669 11.400% |
467,102 (+14.25%) |
Filing History |
| 2023-12-13 4:55 pm Purchase |
2023-12-11 | 13D | Prelude Therapeutics Incorporated PRLD |
Baker Bros. Advisors LP | 10,222,968 24.300% |
3,888 (+0.04%) |
Filing History |
| 2023-11-24 1:43 pm Purchase |
2023-11-21 | 13D | Bellicum Pharmaceuticals, Inc. BLCM |
Baker Bros. Advisors LP | 2,365,472 19.990% |
167,553 (+7.62%) |
Filing History |
| 2023-11-21 5:24 pm Sale |
2023-11-17 | 13D | Madrigal Pharmaceuticals, Inc. MDGL |
Baker Bros. Advisors LP | 1,987,702 9.990% |
-28,058 (-1.39%) |
Filing History |
| 2023-11-14 5:18 pm Sale |
2023-11-14 | 13D | BeiGene, Ltd. ONC |
Baker Bros. Advisors LP | 138,678,037 13.000% |
-14,300,000 (-9.35%) |
Filing History |
| 2023-11-13 4:22 pm Purchase |
2023-10-31 | 13G | Cerus Corporation CERS |
Baker Bros. Advisors LP | 19,101,876 10.500% |
3,014,454 (+18.74%) |
Filing History |
| 2023-10-10 4:42 pm Purchase |
2023-10-05 | 13D | Neoleukin Therapeutics, Inc. NLTX |
Baker Bros. Advisors LP | 473,667 19.990% |
473,667 (New Position) |
Filing History |